Biolinq Incorporated appears in FDA records at 10260 Sorrento Valley Rd., San Diego, California 92121, the address given on its De Novo classification order and its 510(k) clearance letter. The company's documented device is the Biolinq Shine Autonomous Time-in-Range Microsensor, which FDA classifies as a glucose range monitoring system under 21 CFR 862.1359, product code SFU, in Class II with special controls. The record set covers two distinct regulatory events: a De Novo request granted in September 2025 and a 510(k) cleared in September 2026 for a change from prescription-only to over-the-counter use. [1][2][5][8]
The documented device and its components
FDA's 510(k) decision summary describes the Biolinq Shine Autonomous Time-in-Range Microsensor as a continuous intradermal glucose sensor with a color-changing indicator. The manufacturer's technical manual identifies the device as Biolinq Shine, model 82000, and lists kit contents as one sensor in an applicator, one set of instructions and one sensor cover made of medical tape. The manual names Biolinq Incorporated as manufacturer at the Sorrento Valley Road address and lists customer support contact details. [5][9]
The technical manual carries a revision date of August 28, 2026 and document identifiers 60136-1 and LBL-00057 Rev. 12. It states that Biolinq and Biolinq Shine are trademarks of Biolinq Incorporated in the United States and other countries. No parent company, brand owner or corporate website is verified in these records beyond the manufacturer's own published contact information. [9]
De Novo classification, December 2024 to September 2025
Biolinq filed De Novo request DEN240080, dated December 26, 2024 and received December 27, 2024. FDA granted the request on September 23, 2025, classifying the device as Class II with special controls under 21 CFR 862.1359 and product code SFU, in the Clinical Chemistry panel. The classification order is addressed to Kate Hunter, Senior Director, Regulatory Affairs, and is signed by Marianela Perez-Torres, Ph.D., Director of the Division of Chemistry and Toxicology Devices. [6][8]
The De Novo decision summary states that the request was granted and that the device is subject to the special controls identified in the granting letter. The summary discusses risks of hypoglycemia or hyperglycemia related to inaccuracy in the context of the device's output and intended use population. FDA's classification database records the decision as granted, with no predetermined change control plan authorized. [4][6]
510(k) clearance for over-the-counter use, 2026
Biolinq submitted 510(k) K262599, received July 27, 2026, and FDA issued a substantially equivalent decision on September 18, 2026. The decision summary states the purpose of the submission as a modification from prescription use only to over-the-counter use. The clearance letter is addressed to Aly Alvarez, Director, Regulatory Affairs, and lists the device under 21 CFR 862.1359, Class II, product code SFU, as a Traditional clearance. [1][2][5]
The 510(k) decision summary states that no clinical studies were submitted with the notification and that clinical data provided in DEN240080 remains applicable to the device. It also states that no other supportive device performance characteristics data were provided and that the labeling supports the finding of substantial equivalence. The clearance letter states that the device was reviewed for its intended over-the-counter use. [2][5]
What the filing record shows
The linked filing collection contains one 510(k) record, K262599, with a substantially equivalent decision, and the same single record appears in the smaller record sample. These counts describe the filings linked in this snapshot and do not represent total company sales, total portfolio or safety performance. No recall records appear in the linked sample. [1]
The two decisions establish a sequence: a De Novo grant creating the Class II classification and special controls, followed by a 510(k) covering a change in use setting. Both records name Biolinq Incorporated as applicant and carry the same San Diego address, and both reference regulation 21 CFR 862.1359 and product code SFU. [1][2][5][8]

